Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14740338.2021.1867103 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dasatinib-Induced Bilateral Chylothorax: A Case Report.
Cureus
September 2024
Internal Medicine, AdventHealth Waterman, Tavares, USA.
Article Synopsis
- Dasatinib is a medication used to treat Philadelphia-positive chronic myeloid leukemia (CML), but it can cause complications, one of which is chylothorax—a buildup of fluid in the chest.
- A case of a 79-year-old female who developed acute breathing issues while on dasatinib revealed bilateral chylothorax, leading to the conclusion that the medication was likely the cause, as no other risk factors were found.
- After stopping dasatinib and switching to bosutinib, along with a low-fat diet, the patient showed no recurrence of chylothorax six months later, highlighting the need for awareness and management strategies regarding this complication
Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML.
Ann Hematol
June 2024
Division of Malignant Hematology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Dasatinib is one of the second generation tyrosine kinase inhibitors (TKI) which is approved for the treatment of patients with chronic phase CML (CP-CML) both in the front line and in the second line setting. Pleural effusion (PE) is a unique toxicity associated with dasatinib use. Our aim was to study the incidence of pleural effusion in our cohort of patients who were treated with dasatinib for CP-CML and the safety upon TKI switch.
View Article and Find Full Text PDFFluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study.
BMJ Open
August 2023
Department of Pharmacy, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China
Objectives: This study aimed to conduct a thorough analysis of fluid retention-associated adverse events (AEs) associated with BCR::ABL inhibitors.
Design: A retrospective pharmacovigilance study.
Setting: Food and Drug Administration Adverse Event Reporting System (FAERS) database for BCR::ABL inhibitors was searched from 1 January 2004 to 30 September 2021.
Development of a human herpesvirus 8-negative effusion-based lymphoma during treatment with dasatinib for chronic myeloid leukemia.
J Clin Exp Hematop
March 2023
Department of Internal Medicine, Nippon Koukan Hospital, Kanagawa, Japan.
We present the case of an 85-year-old male patient diagnosed with human herpesvirus 8 (HHV8)-negative effusion-based lymphoma (EBL) that developed from long-lasting pleural effusion (PE) induced by dasatinib treatment for chronic myeloid leukemia (CML). After the onset of this disorder, dasatinib treatment was discontinued and drainage was performed to regress the effusion. The major molecular response (MMR) was thus lost.
View Article and Find Full Text PDFSuccessful Dasatinib Treatment of Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinoma and -Positive Chronic Myeloid Leukemia: A Case Report.
Case Rep Oncol
December 2022
Department of Hematology, Daini Osaka Police Hospital, Osaka, Japan.
Dasatinib, a second-generation tyrosine kinase inhibitor (TKI), inhibits multiple kinase pathways and is a promising anti-tumor agent for various solid tumors, including lung cancer. Herein, we report a patient with coexisting epidermal growth factor receptor ()-mutant lung adenocarcinoma and -positive chronic myeloid leukemia (CML). The patient received afatinib for a postoperative intrapulmonary recurrence of lung adenocarcinoma harboring exon 19 deletion.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!